AGEN
Price
$0.68
Change
-$0.00 (-0.00%)
Updated
Feb 23, 6:59 PM EST
19 days until earnings call
DNLI
Price
$16.93
Change
+$0.10 (+0.59%)
Updated
Feb 23, 6:59 PM EST
2 days until earnings call
Ad is loading...

Compare trend and price AGEN vs DNLI

Header iconAGEN vs DNLI Comparison
Open Charts AGEN vs DNLIBanner chart's image
Agenus
Price$0.68
Change-$0.00 (-0.00%)
Volume$5.66M
CapitalizationN/A
Denali Therapeutics
Price$16.93
Change+$0.10 (+0.59%)
Volume$601.5K
CapitalizationN/A
View a ticker or compare two or three
AGEN vs DNLI Comparison Chart

Loading...

AGENDaily Signal changed days agoGain/Loss if shorted
 
Show more...
DNLIDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
AGEN vs. DNLI commentary
Feb 24, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AGEN is a StrongSell and DNLI is a StrongBuy.

COMPARISON
Comparison
Feb 24, 2024
Stock price -- (AGEN: $0.68 vs. DNLI: $16.93)
Brand notoriety: AGEN and DNLI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AGEN: 66% vs. DNLI: 105%
Market capitalization -- AGEN: $260.22M vs. DNLI: $2.34B
AGEN [@Biotechnology] is valued at $260.22M. DNLI’s [@Biotechnology] market capitalization is $2.34B. The market cap for tickers in the [@Biotechnology] industry ranges from $552.93B to $0. The average market capitalization across the [@Biotechnology] industry is $2.59B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AGEN’s FA Score shows that 0 FA rating(s) are green whileDNLI’s FA Score has 0 green FA rating(s).

  • AGEN’s FA Score: 0 green, 5 red.
  • DNLI’s FA Score: 0 green, 5 red.
According to our system of comparison, AGEN is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AGEN’s TA Score shows that 4 TA indicator(s) are bullish while DNLI’s TA Score has 4 bullish TA indicator(s).

  • AGEN’s TA Score: 4 bullish, 5 bearish.
  • DNLI’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, DNLI is a better buy in the short-term than AGEN.

Price Growth

AGEN (@Biotechnology) experienced а +4.12% price change this week, while DNLI (@Biotechnology) price change was -0.53% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.03%. For the same industry, the average monthly price growth was +18.51%, and the average quarterly price growth was +38.88%.

Reported Earning Dates

AGEN is expected to report earnings on May 09, 2024.

DNLI is expected to report earnings on May 02, 2024.

Industries' Descriptions

@Biotechnology (+2.03% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for AGEN with price predictions.
OPEN
A.I.dvisor published
a Summary for DNLI with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
DNLI($2.34B) has a higher market cap than AGEN($260M). DNLI has higher P/E ratio than AGEN: DNLI (62.89) vs AGEN (12.89). AGEN YTD gains are higher at: -17.611 vs. DNLI (-21.109). DNLI has higher annual earnings (EBITDA): -150.83M vs. AGEN (-201.61M). DNLI has more cash in the bank: 1.11B vs. AGEN (106M). DNLI has less debt than AGEN: DNLI (53.9M) vs AGEN (89M). DNLI has higher revenues than AGEN: DNLI (341M) vs AGEN (101M).
AGENDNLIAGEN / DNLI
Capitalization260M2.34B11%
EBITDA-201.61M-150.83M134%
Gain YTD-17.611-21.10983%
P/E Ratio12.8962.8920%
Revenue101M341M30%
Total Cash106M1.11B10%
Total Debt89M53.9M165%
FUNDAMENTALS RATINGS
AGEN vs DNLI: Fundamental Ratings
AGEN
DNLI
OUTLOOK RATING
1..100
2112
VALUATION
overvalued / fair valued / undervalued
1..100
96
Overvalued
80
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10090
PRICE GROWTH RATING
1..100
6374
P/E GROWTH RATING
1..100
6595
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DNLI's Valuation (80) in the Biotechnology industry is in the same range as AGEN (96). This means that DNLI’s stock grew similarly to AGEN’s over the last 12 months.

DNLI's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as AGEN (100). This means that DNLI’s stock grew similarly to AGEN’s over the last 12 months.

DNLI's SMR Rating (90) in the Biotechnology industry is in the same range as AGEN (100). This means that DNLI’s stock grew similarly to AGEN’s over the last 12 months.

AGEN's Price Growth Rating (63) in the Biotechnology industry is in the same range as DNLI (74). This means that AGEN’s stock grew similarly to DNLI’s over the last 12 months.

AGEN's P/E Growth Rating (65) in the Biotechnology industry is in the same range as DNLI (95). This means that AGEN’s stock grew similarly to DNLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AGENDNLI
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
75%
Momentum
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
82%
MACD
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
81%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
83%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
76%
Bearish Trend 1 day ago
85%
Advances
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
79%
Declines
ODDS (%)
N/A
Bearish Trend 4 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
76%
Aroon
ODDS (%)
Bullish Trend 1 day ago
75%
Bearish Trend 1 day ago
85%
View a ticker or compare two or three
Ad is loading...
AGENDaily Signal changed days agoGain/Loss if shorted
 
Show more...
DNLIDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BALSX11.000.09
+0.82%
BlackRock U.S. Insights Lon/Shr Eq Inv A
IMIDX25.810.13
+0.51%
Congress Mid Cap Growth Institutional
ICVPX15.960.06
+0.38%
VY® Columbia Small Cap Value II S2
SSSVX381.020.13
+0.03%
State Street Equity 500 Index A
ALBAX67.61-0.02
-0.03%
Alger Growth & Income A

AGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, AGEN has been loosely correlated with CRSP. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if AGEN jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AGEN
1D Price
Change %
AGEN100%
+1.05%
CRSP - AGEN
49%
Loosely correlated
-2.55%
NTLA - AGEN
45%
Loosely correlated
-3.97%
AXON - AGEN
42%
Loosely correlated
-0.34%
INVA - AGEN
40%
Loosely correlated
N/A
AKRO - AGEN
39%
Loosely correlated
+4.67%
More

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been closely correlated with NTLA. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if DNLI jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
+0.59%
NTLA - DNLI
68%
Closely correlated
-3.97%
BEAM - DNLI
65%
Loosely correlated
+1.46%
VCYT - DNLI
61%
Loosely correlated
-8.87%
EDIT - DNLI
59%
Loosely correlated
-1.45%
ADPT - DNLI
54%
Loosely correlated
+4.12%
More